Abstract | OBJECTIVE: To determine the response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell multicentric or thymic lymphoma. DESIGN: Retrospective case series. ANIMALS: PROCEDURES: Medical records of dogs in which lymphoma was diagnosed between February 2006 and October 2008 were reviewed. Entry criteria included that dogs had a confirmed lymphoma that was immunophenotyped to be of B-cell or T-cell origin. Only dogs that received doxorubicin alone as their first chemotherapy treatment and were evaluated 1 week later were included in the study. Dogs were excluded when they had received prior treatment with corticosteroids. Medical records were reviewed to obtain signalment, stage and substage of lymphoma, and immunophenotype and to determine whether the dog had hypercalcemia at the time of diagnosis. RESULTS: CONCLUSIONS AND CLINICAL RELEVANCE:
|
Authors | Lynda M Beaver, Gabriele Strottner, Mary K Klein |
Journal | Journal of the American Veterinary Medical Association
(J Am Vet Med Assoc)
Vol. 237
Issue 9
Pg. 1052-5
(Nov 01 2010)
ISSN: 0003-1488 [Print] United States |
PMID | 21034344
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Doxorubicin
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Dog Diseases
(drug therapy)
- Dogs
- Doxorubicin
(administration & dosage, therapeutic use)
- Female
- Lymphoma, B-Cell
(drug therapy, veterinary)
- Lymphoma, T-Cell
(drug therapy, veterinary)
- Male
- Retrospective Studies
|